Products
Roxadustat (FG-4592) Blood ID 90
| Incidents 5 | Type | Date |
|---|---|---|
| Oyarzún appeal | Appeal against sanction | 08/08/2017 |
| Androni Giocattoli appeal | Appeal against sanction | 30/10/2015 |
| Androni Giocattoli team suspension | Temporary suspension | 01/08/2015 |
| Oyarzún positive | Positive test | 15/07/2015 |
| Taborre positive | Positive test | 16/06/2015 |
| People | Nationality |
|---|---|
| Oyarzún Carlos |  |
| Savio Gianni |  |
| Taborre Fabio | |
Sources
- Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia, News Medical, accessed 12/12/2012
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis, ClinicalTrials.gov, accessed 25/06/2013
- AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease, Astra Zeneca, accessed 31/07/2013
- Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD, American Journal of Kidney Diseases, accessed 04/09/2016
